Sarah Bhagat brings an unusually deep scientific background to venture capital, holding a Ph.D. in Neuroscience from Yale and completing a psychiatry postdoc at Stanford before entering investing. She has built a reputation as a hands-on partner who serves on multiple boards and focuses on scientifically ambitious therapeutics companies across areas like gene therapy, immuno-oncology, and CNS conditions rather than sticking to conventional therapeutic areas.